Skip to main content

Table 1 Summary information of the characteristics of participants from included studies contributing to statistical analyses

From: Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis

Characteristics

No. of patients, or range of median

Gender, n (%) (ntotal = 888)

 

 Male

557 (62.7)

 Female

331 (37.3)

Age (years) (ntotal = 736)

 

 Range

34–91

Newly diagnosed or relapsed/refractory, n (%) (ntotal = 997)

 

 Newly diagnosed

28 (2.8)

 Relapsed/refractory

489 (49.0)

 Mixed population

254 (25.5)

 Not reported

226 (22.7)

AL isotype, n (%) (ntotal = 441)

 

 λ

387 (87.8)

 k

54 (12.2)

Mayo 2004 Stage, n (%) (ntotal = 303)

 

 I

49 (16.2)

 II

123 (40.6)

 III

50 (16.5)

 IIIA

60 (19.8)

 IIIB

21 (6.9)

Mayo 2012 Stage, n (%) (ntotal = 109)

 

 I

14 (12.8)

 II

36 (33.0)

 III

33 (30.3)

 IV

26 (23.9)

Involved organs, n (%) (ntotal = 936)

 

 Heart

688 (74.3)

 Kidney

560 (60.5)

 Liver

76 (8.2)

 Others*

34 (3.7)

eGFR (mL/min/m2) (ntotal = 330)

 

 Range of median

34–73

dFLC (mg/L) (ntotal = 711)

 

 Range of median

34.5–276.9

  1. dFLC  difference between the involved and uninvolved light chain, eGFR  epidermal growth factor receptor
  2. *Pulmonary, tongue, bone marrow, muscle, spleen, upper aerodigestive tract